Clinical trials: Cognitively Normal
Frontotemporal Lobar Degeneration, Alzheimer Disease
PET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using [18F]-PI-2620
The investigators will compare [18F]-PI-2620 tau PET scans from patients with frontotemporal lobar degeneration (FTLD), patients with non-amnestic presentations of Alzheimer's disease (naAD), and demographically matched…
- Conditions
- Frontotemporal Lobar Degeneration, Alzheimer Disease, Cognitively Normal
- Trial name
- NCT05456503
- Testing
- [18F]-PI-2620
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Elderly, Alzheimer Disease
Orexin and Tau Pathology in Cognitively Normal Elderly
Alzheimer's disease (AD) is a common neurodegenerative disease characterized by the accumulation of amyloid plaques and neurofibrillary tangles.
- Trial name
- NCT03053908
- Testing
- Actigraphy, Nocturnal Polysomnograpahy (NPSG)
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- NYU Langone Health
Mild Cognitive Impairment Due to Alzheimer's Disease
Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset
The purpose of this study is to qualify the biomarker risk algorithm for prognosis of the risk of developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI-AD), and also to evaluate the efficacy of pioglitazone…
- Trial name
- TOMMORROW (NCT01931566)
- Testing
- Pioglitazone
- Where
- 55 sites in United States, Australia and 3 more
- Volunteers
- 3,494 people, healthy volunteers welcome
- Sponsor
- Takeda
Mild Cognitive Impairment (MCI), Alzheimer Dementia (AD)
Predicting Pre-dementia
The goal of this observational study is to learn how well a multimodal "Progression and Risk" (PR) model can predict and stage early mild cognitive impairment (MCI) due to Alzheimer's disease in cognitively normal or very mildly…
- Conditions
- Mild Cognitive Impairment (MCI), Alzheimer Dementia (AD), Alzheimer Disease (AD), APOE-4 Positive
- Trial name
- NCT07516119
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Prevention Research Consortium Corp.
Alzheimer Disease, Neurofibrillary Tangle
Analysis of 18F-XTR006 PET Imaging in Cognitively Normal Subjects, and Patients With MCI and AD
The goal of this clinical trial is to evaluate the efficacy and safety of XTR006 injection PET visual reading in detecting brain neurofibrillary tangles (NFTs) in elderly subjects with Mild Cognitive Impairment (MCI), Alzheimer's…
- Trial name
- NCT07115238
- Testing
- XTR006
- Where
- China
- Volunteers
- 354 people, healthy volunteers welcome
- Sponsor
- Sinotau Pharmaceutical Group
Alzheimer's Disease
A Study to Assess Regional Cerebral Blood Flow as an Alzheimer's Disease Biomarker Compared to Positron Emission Tomography in Patients With Mild-to-Moderate Alzheimer's Disease and Cognitively Normal Elderly Subjects (Study MK-0000-068)(COMPLETED)
The aim of the study is to determine if regional cerebral blood flow, measured by dynamic arterial spin labeling (dASL), can be a biomarker for stage of Alzheimer's disease.
- Trial name
- NCT00757939
- Testing
- MRI, FDG-PET
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Metabolic Syndrome, Normal Cognition
Ketone Ester Effects on Biomarkers of Brain Metabolism and Cognitive Performance in Cognitively Intact Adults 55 Years Old or Older
Background: In Alzheimer s disease (AD) the brain cannot use glucose as a fuel. The brain can use ketones as a fuel instead of glucose. Researchers want to test a supplement, Ketone Ester (KE).
- Trial name
- NCT04421014
- Testing
- Ketone Ester drink
- Where
- United States
- Volunteers
- 99 people
- Sponsor
- National Institute on Aging (NIA)
Neurotypical, Cognitively Normal
Brain Vascular and Neural Function Linked to Balance Across the Adult Lifespan
This is a single-arm, two-visit, non-randomized, cross sectional study identified as an intervention due to the use of a single bout of aerobic exercise to assess cerebrovascular function under the NIH rules.
- Trial name
- NCT06127667
- Testing
- aerobic exercise
- Where
- United States
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Glioma, Fear of Cancer
FearLess in Cognitively Intact Patients With Glioma
This study will assess the preliminary feasibility and acceptability of FearLess, a newly-developed psychological intervention for fear of cancer recurrence (FCR) among cognitively-intact patients with glioma.
- Trial name
- FearLess (NCT05604365)
- Testing
- FearLess Intervention
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Virginia Commonwealth University
Alzheimer's Disease
Effects of Simvastatin on Biomarkers
A year-long randomized, double-blind, placebo-controlled trial of simvastatin to see if it produces beneficial changes in cerebral spinal fluid proteins associated with Alzheimer's disease.
- Trial name
- SimBio (NCT01142336)
- Testing
- Simvastatin
- Where
- United States
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- University of Washington
Genetic Predisposition to Disease, Healthy Volunteers
This Study Consists of Two Study Parts Conducted Under a Single IRB. Part I: Short Term ApoE-dependent Cerebral Blood Flow Response to Sirolimus in Cognitively Normal Adults Part II: Short Term ApoE-dependent Cerebral Blood Flow and Lung Perfusion Response to Sirolimus in Cognitively Normal Adults
This study consists of two study parts (Part I and Part II) conducted under a single IRB approval. Individuals that participated in Part I of the study were invited to participate in Part II of the study.
- Trial name
- NCT05386914
- Testing
- Sirolimus
- Where
- United States
- Volunteers
- 205 people, healthy volunteers welcome
- Sponsor
- University of Missouri-Columbia
Alzheimer Disease
The Sleep Amyloid, Slow WAve Race and Ethnicity Study
African-Americans (AAs) have an increased prevalence of both Alzheimer's disease (AD) and vascular risk factors for AD such as diabetes and hypertension when compared to whites.
- Trial name
- Sleep AWARE (NCT03814603)
- Testing
- PET-MR Scan, PiB
- Where
- United States
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Sleep Disordered Breathing, Alzheimer's Disease
Sleep, Aging and Risk for Alzheimer's Disease
Our preliminary data show for in cognitively-normal elderly, that Sleep Disordered Breathing (SDB) is associated with the increase of cerebrospinal fluid (CSF) phosphorylated-Tau (P-Tau) and total-Tau (T-Tau), decreases in medial…
- Trial name
- SARA (NCT01962779)
- Testing
- Continuous positive airway pressure (CPAP)
- Where
- 2 sites in United States
- Volunteers
- 235 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Alzheimer's Disease, Cognitive Impairment
Effect of EGb761® on Brain Glucose Metabolism in Three Groups of Elderly Defined by Cognitive Functions
The aim of the study is to evaluate the effect of EGb761®, in comparison to placebo, on cerebral glucose metabolism, in three groups of elderly patients: newly diagnosed mild Alzheimer's disease (AD), memory complaint patients…
- Trial name
- NCT00814346
- Testing
- EGb761®
- Where
- 8 sites in France
- Volunteers
- 49 people
- Sponsor
- Ipsen
Hippocampal Hyperactivation, Prodromal Alzheimer Disease
Levetiracetam for Persons at Risk for Alzheimer's Disease
The goal of this clinical trial is to investigate whether very small doses of a drug called levetiracetam (LEV) may reduce elevated brain signaling in individuals who are at an increased risk for developing Alzheimer's Disease…
- Trial name
- ALEVIATE-2 (NCT07477431)
- Testing
- Levetiracetam (LEV)
- Where
- 2 sites in Canada
- Volunteers
- 40 people
- Sponsor
- Sunnybrook Health Sciences Centre
Alzheimer's Disease, Mild Cognitive Impairment
[18F]THK-5351 Positron Emission Computed Tomography Study of Normal, Mild Cognitive Impairment, Alzheimer's Disease and Other Neurodegenerative Disease
This is a cross-sectional and longitudinal study to evaluate the clinical utility of [18F]THK-5351 positron emission computed tomography in cognitively healthy volunteers, mild cognitive impairment (MCI), Alzheimer's disease (AD)…
- Conditions
- Alzheimer's Disease, Mild Cognitive Impairment, Neurodegenerative Diseases
- Trial name
- NCT02656498
- Testing
- [18F]THK-5351
- Where
- 2 sites in South Korea
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- Jae Seung Kim
Alzheimer Disease, Family Members
Gamma Light and Sound Stimulation to Prevent Dementia in Cognitively Normal People at Risk for Alzheimer's Disease
Alzheimer's disease (AD) is characterized by significant memory loss, toxic protein deposits (amyloid and tau) in the brain, and changes in the gamma frequency band on EEG.
- Trial name
- NCT05776641
- Testing
- GENUS
- Where
- 2 sites in United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Aging, Cognitive Aging
Music Improvisation Training on Cognitive Function in Older Adults
This project will study the effects and mechanisms of a music improvisation training intervention on self-regulation of older adults with and without MCI.
- Conditions
- Aging, Cognitive Aging, Cognitive Impairment, Cognitive Training
- Trial name
- Music Training (NCT06721390)
- Testing
- Piano Improvisation, Music Listening
- Where
- United States
- Volunteers
- 238 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Late Onset Alzheimer Disease
Measuring Brain Amyloid Plaque Load in Older Adults Using BAY 94-9172
The overall goal of this project is to establish and validate biomarkers associated with the risk and progression of late onset Alzheimer's disease, mild cognitive impairment and cognitive decline.
- Trial name
- NCT01222351
- Testing
- BAY 94-9172 (Florbetaben)
- Where
- United States
- Volunteers
- 161 people
- Sponsor
- New York State Psychiatric Institute
Mild Cognitive Impairment, Alzheimer's Disease
Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia
Bio-Hermes-002 is a 120-day cross-sectional study that will result in a blood, CSF, retinal, digital, MRI, and PET brain imaging biomarker database that can be used to determine the primary objective.
- Conditions
- Mild Cognitive Impairment, Alzheimer's Disease, Alzheimer's Disease, Early Onset, Memory Loss
- Trial name
- Bio-Hermes-002 (NCT06584357)
- Testing
- Biomarker Data Collection, MK6240
- Where
- 26 sites in United States, Canada and 1 more
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- GAP Innovations, PBC